AVADEL PHARMACEUTICALS PLC 4

Director Eric J. Ende tendered 219,905 Avadel Pharmaceuticals plc ordinary shares at $21.00 per share and canceled options on 219,057 shares for cash and CVRs in connection with Alkermes plc’s acquisition of Avadel.

On February 12, 2026, Eric J. Ende disposed of all of his equity interests in Avadel Pharmaceuticals plc in connection with the cash acquisition of Avadel by Alkermes plc under a scheme of arrangement. His 219,905 ordinary shares, including previously restricted stock that fully vested at closing, were converted into $21.00 per share in cash plus one contingent value right (CVR) per share, implying cash proceeds of roughly $4.6 million (excluding any CVR value). In addition, multiple tranches of stock options (exercise prices ranging from $1.49 to $16.32 and expirations from 2029 to 2035) covering 219,057 shares in aggregate were canceled and converted into cash equal to the in-the-money value based on the $21.00 cash consideration, plus one CVR for each underlying share; the combined in-the-money option value is approximately $3.2 million, making this a large, non‑routine, change‑of‑control‑driven disposition rather than an open‑market sale. Following the transaction, Ende no longer holds ordinary shares or options of Avadel, as the issuer has been acquired.

Filing Facts

CIK

1012477

Ticker

AVDL

Form

4

Source Type

sec

Accession

0001104659-26-014442

Alert Tier

7